Q2 2026 Preview: 6 FDA Decisions to Watch

The first quarter of 2026 established a brisk regulatory pace that Q2 shows no signs of slowing. In the span of 3 months, the United States Food and Drug Administration (US FDA) cleared deucravacitinib for psoriatic arthritis (PsA) — the first TYK2 inhibitor approved for the indication — navepegritide for achondroplasia, and sublingual epinephrine film as the first needle-free epinephrine option for anaphylaxis. The Commissioner's National Priority Voucher program continued to make headlines, most recently with the fastest New Molecular Entity (NME) approval since 2002 in early April.